Page last updated: 2024-08-23

paclitaxel and Dyslipidemia

paclitaxel has been researched along with Dyslipidemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awata, M; Fujita, H; Hara, H; Hozawa, H; Iijima, R; Kawai, K; Matsuyama, Y; Mukawa, H; Muramatsu, T; Nakamura, M; Nanto, S; Ochiai, M; Okada, H; Suwa, S; Yokoi, H	1

Other Studies

1 other study(ies) available for paclitaxel and Dyslipidemia

Article	Year
Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents. The American journal of cardiology, 2016, 09-15, Volume: 118, Issue:6 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Pressure; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Japan; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sirolimus	2016

Article

Year

Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents.

The American journal of cardiology, 2016, 09-15, Volume: 118, Issue:6

Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Pressure; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Japan; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sirolimus

2016